In 2008, Roche went to the Delhi High Court over erlotinib, a lung-cancer drug sold as Tarceva, after Cipla launched a generic version at a fraction of the price. It was the first significant test of what an Indian pharmaceutical patent was actually worth now that India had begun granting product patents on medicines again.
Roche had the patent. Cipla was selling. On paper it looked like the simplest kind of case there is.
The IP move
Roche asked for an interim injunction to take the generic off the market immediately, which is the remedy that usually decides commercial disputes of this kind. The court refused. The reasoning has been quoted ever since: the price gap between the two products was very large, the medicine treated a life-threatening condition, and Cipla had raised a credible challenge to the validity of the patent that deserved to be tried rather than assumed away. The refusal was upheld on appeal, and the Supreme Court declined to disturb it.
Two things followed from that. The generic stayed on sale, and the case went to a full trial on the merits, which is something that almost never happens in Indian IP litigation because most disputes are settled or abandoned at the interim stage. Cipla's defence combined an attack on validity with a technical argument that its product was a different polymorphic form from the one the suit patent covered, so that even a valid patent would not be infringed.
The trial court and the appellate bench that followed it reached different conclusions on infringement, with the appellate stage going Roche's way and the question of what Roche should actually recover working through further proceedings. Roche held a patent for the entire period. What it did not hold, for years, was any practical ability to use it.
The takeaways
A granted patent is a right to litigate, not a switch that removes a competitor from the market.
Interim relief in India is discretionary. Courts weigh public interest, pricing and the apparent strength of the validity challenge, not merely the existence of the certificate.
The commercial outcome here was determined by how long the case took, not by what it eventually held.
A designed-around product, arguing a different form or a different route, is the standard response to a pharmaceutical patent, so claim drafting should anticipate it.
Anyone entering this space needed to know all of the above before committing to a launch plan built on either enforcing the patent or ignoring it.
The lesson for your business
Freedom-to-operate work is not about obtaining a clean bill of health. It is about knowing, before you invest, who holds what in your space, how strong those rights look under inspection, and how courts in your market have actually behaved when somebody tried to enforce rights like them. That last part is the piece companies most often skip, and it is the piece that decides whether enforcement is a real deterrent or an expensive gesture. The answer changes what you build, how you design around, what you budget for, and sometimes whether you launch at all.
